Nu-Med Plus (NUMD) Debt to Equity (2011 - 2021)

Nu-Med Plus has disclosed Debt to Equity across 8 years of filings, most recently posting $0.05 for Q1 2021.

• Debt to Equity for Q1 2021 came in at $0.05, up 115.27% year-over-year; the trailing twelve-month figure through Mar 2021 was $0.05 (up 115.27% YoY), and the FY2020 annual result was $0.02, up 106.51% from the prior year.
• Debt to Equity came in at $0.05 for Q1 2021 at Nu-Med Plus, up from $0.02 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.57 in Q3 2020 to a low of -$0.85 in Q1 2018.
• The 5-year median for Debt to Equity is $0.01 (2020), against an average of -$0.01.
• Peak annual rise in Debt to Equity reached 5945.11% in 2020, while the deepest fall reached 759.29% in 2020.
• Nu-Med Plus' Debt to Equity stood at $0.29 in 2017, then surged by 54.38% to $0.45 in 2018, then plunged by 168.27% to -$0.31 in 2019, then jumped by 106.51% to $0.02 in 2020, then soared by 144.93% to $0.05 in 2021.
• The last three Debt to Equity figures came in at $0.05 (Q1 2021), $0.02 (Q4 2020), and $0.57 (Q3 2020), per Business Quant data.